Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;17(3):210076.
doi: 10.1183/20734735.0076-2021.

The definition of pulmonary hypertension: history, practical implications and current controversies

Affiliations
Review

The definition of pulmonary hypertension: history, practical implications and current controversies

Gabor Kovacs et al. Breathe (Sheff). 2021 Sep.

Abstract

The definition of pulmonary hypertension (PH) is based on a growing body of evidence and represents the result of ongoing discussions within the PH community over the past 50 years. In 2018, the most recent World Symposium on Pulmonary Hypertension introduced significant changes in the definition of PH by lowering the mean pulmonary arterial pressure threshold to >20 mmHg and (re)introducing the pulmonary vascular resistance ≥3 WU cut-off for all forms of pre-capillary PH. These changes and their potential clinical impact have been the subject of lively discussions in the community and some important questions and controversies have been identified. In this review we aim to present the development of the definition of PH over the past decades and discuss the main arguments that led to relevant modifications. In addition, we address the practical implications of the most recent changes and controversies that still exist.

Educational aims: To review the historical development of the definition of pulmonary hypertension.To discuss practical implications and current controversies of the currently recommended definitions of pulmonary hypertension and pulmonary arterial hypertension.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: G. Kovacs reports personal fees and non-financial support from Actelion, Janssen, Bayer, GSK, MSD, Boehringer Ingelheim, Novartis, Chiesi, Vitalaire, Ferrer, AOP outside the submitted work. Conflict of interest: H. Olschewski reports grants from Bayer, Unither Pharmaceuticals, Actelion Pharmaceuticals Ltd., Roche, Boehringer Ingelheim and Pfizer Inc., personal fees from Gilead Sciences Inc., Encysive Pharmaceuticals Ltd. and Nebu-Tec, personal fees and non-financial support from Bayer, Unither Pharmaceuticals, Actelion Pharmaceuticals Ltd., Pfizer Inc., Eli Lilly, Novartis, AstraZeneca, Boehringer Ingelheim, Chiesi, Menarini, MSD and GSK outside the submitted work.

Figures

Figure 1
Figure 1
Right heart catheter tracings of pulmonary arterial pressure and PAWP. a) By inflating the balloon of the Swan-Ganz catheter, the transition of the pulmonary arterial pressure curve to the PAWP curve may be observed. b) Pulmonary arterial pressure curve in a patient with severe PH. c) Pulmonary arterial pressure curve in a patient with normal pulmonary ­haemodynamics. PVR is calculated as (mPAP–PAWP)/cardiac output. The blue curve represents the pulmonary arterial pressure curve (courtesy of Philipp Douschan (Dept of Internal Medicine, Division of Pulmonology, Medical University of Graz, Graz, Austria) and Khodr Tello (Dept of Internal Medicine, Justus-Liebig-University Giessen, Giessen, Germany)).

References

    1. Simonneau G, Montani D, Celermajer DS, et al. . Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53: 1801913. doi:10.1183/13993003.01913-2018 - DOI - PMC - PubMed
    1. Hatano S, Strasser T. Primary Pulmonary Hypertension: Report on a WHO Meeting, Geneva, 15-17 October 1973. Geneva, WHO, 1975. https://apps.who.int/iris/handle/10665/39094
    1. WHO Expert Committee on Chronic Cor Pulmonale & World Health Organization. Chronic cor pulmonale: report of an Expert Committee [meeting held in Geneva from 10 to 15 October 1960]. Geneva, WHO, 1961. https://apps.who.int/iris/handle/10665/40483
    1. Rich S. Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998, Evian, France, September 6–10. 1998. Geneva, WHO, 1998.
    1. Barst RJ, McGoon M, Torbicki A, et al. . Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 40S–47S. doi:10.1016/j.jacc.2004.02.032 - DOI - PubMed

LinkOut - more resources